Skip to main content

Table 1 Demographics and clinical characteristics of 139 subjects

From: Collateral damage of using colistin in hospitalized patients on emergence of colistin-resistant Escherichia coli and Klebsiella pneumoniae colonization and infection

Variables

Values

Female gender, n (%)

70 (50.4%)

Age (yrs), mean ± SD

67.2 ± 15.9

Comorbid conditions, n (%)

131 (94.2%)

 Diabetes mellitus

53 (38.1%)

 Cardiovascular diseases

41 (29.5%)

 Renal diseases

37 (26.6%)

 Cerebrovascular diseases

35 (25.2%)

 Solid malignancy

21 (15.1%)

 Chronic pulmonary diseases

20 (14.3%)

 Hematologic malignancy

16 (11.5%)

 Liver diseases

10 (7.2%)

 Organ transplantation

4 (2.9%)

 HIV infection

2 (1.4%)

Previous hospitalization within 3 months, n (%)

73 (52.5%)

Site of infection in 139 patients at enrollment, n (%)

 Lower respiratory tract infection

93 (66.9%)

 Blood stream infection

40 (28.8%)

 Urinary tract infection

18 (12.9%)

 Gastrointestinal tract infection

11 (7.9%)

 Skin and soft tissue infection

8 (5.8%)

 Surgical site infection

1 (0.7%)

 Bone and joint infection

1 (0.7%)

Documented bacteria-caused infections in 110 patients that required colistin therapy, n (%)

 A. baumannii

79 (71.8%)

 K. pneumoniae

18 (16.4%)

 P. aeruginosa

9 (8.2%)

 E. coli

2 (1.8%)

 E. cloacae

2 (1.8%)

Medical procedure, n (%)

 Mechanical ventilation

117 (84.2%)

 Central venous catheterization

85 (61.2%)

 Chronic intermittent hemodialysis

53 (38.1%)

Severity of patient illness, mean ± SD

 APACHE II score at enrollment

21.8 ± 7.4

Antibiotic use for the current hospitalization prior to study enrollment, n (%)

134 (96.4%)

 Carbapenems

112 (80.6%)

 Cephalosporins

56 (40.3%)

 Beta-lactam/beta-lactamase inhibitors

75 (54.0%)

 Fluoroquinolones

39 (28.1%)

 Vancomycin

43 (30.9%)

 Aminoglycosides

6 (4.3%)

 Colistin

9 (6.8%)

Colistin use within 3 months prior to study enrollment, n (%)

15 (10.8%)